References
- Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
- Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
- Herold M, Pasold R, Srock S, et al. Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL). Blood 2004; 104, (abstract 584)
- Forstpointer R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071
- Leoni L M, Bailey B, Reifert J, et al. SDX-105 (Bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action. Blood 2003; 102, (abstract 2363)
- Bremer K, Roth W. Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas. Tumordiagn u Ther 1996; 17: 1–6
- Bremer K. High rates of long lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol 2002; 128: 603–609
- Weide R, Heymanns J, Gores A, Köppler H. Bendamustine, mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma 2002; 43: 327–331
- Weide R, Pandorf A, Heymanns J, Köppler H. Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient immuno-chemotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004; 45: 2445–2449
- Cheson B D, Horning S J, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244–1253
- Balfour J A, Goa K L. Bendamustine. Drugs 2001; 61: 631–640
- Ozegowski W, Krebs D. IMET 3393, gamma-(1-methyl-5-bis-(ß-chloräthyl)-amino-benzimidazolyl(2))-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste. Zbl Pharm 1971; 110: 1013–1019
- Anger G, Hesse P, Köhler P, Baufeld H. Erste klinische Erfahrungen mit einem neuen Zytostatikum. Deutsch Gesundheitswes 1967; 22: 1079–1084
- Ruffert K, Jahn H, Syrbe G, et al. Cytostasan (Bendamustin) in der alternativtherapie maligner non-Hodgkin-lymphoma. Z Klin Med 1989; 44: 671–674
- Anger G, Fink R, Fleischer J, et al. Vergleichsuntersuchungen zwischen cytostasan und cyclophosphamid bei der chronischen lymphadenose, dem plasmozytom, der lymphogranulomatose und dem bronchialkarzinom. Deutsch Gesundheitswes 1975; 30: 1280–1285
- Friedberg J W, Cohen P, Cheson B D, et al. Bendamustine HCL (Treanda™) treatment results in high rates of objective response in patients with rituximab-refractory and alkylator-refractory indolent B-cell non-Hodgkin's lymphoma (NHL): results from a phase II multicenter single-agent study (SDX-105-01). Blood 2005; 106, (abstract 229)
- Weide R, Heymanns J, Koeppler H. Successful treatment of alkylating agent resistant low grade B-cell non-hodgkin's lymphomas with bendamustin/mitoxantrone/rituximab (BMR). Onkologie 1999; 22(Suppl 1), (abstract 644)
- Rummel M J, Al-Batran S E, Kim S Z, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383–3389
- Robinson K S, Williams M E, Cohen P, et al. Bendamustine HCL (Treanda™) treatment in combination with rituximab results in objective responses in patients with refractory/relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: results from phase II multicenter study (SDX-105-02). Blood 2005; 106, (abstract 923)